#United States #Franklin Lakes #Revello Stent #Nitens Stent #BD Technologies

BD's Latest Innovation: The Revello Stent

BD (Becton, Dickinson and Company), a prominent leader in medical technology, has made significant strides with its introduction of the Revello vascular covered stent. This innovative device has just received its CE mark, allowing it to be utilized across the European Union. The Revello stent is poised to provide a groundbreaking solution for treating atherosclerotic lesions in the common and external iliac arteries, addressing critical health issues facing the aging population in Europe.

Addressing Aortic Artery Disease

Peripheral artery disease (PAD) represents a significant burden on aging populations, particularly concerning the iliac arteries. This condition can lead to severe complications and disability. The Revello stent is designed to enhance treatment for these complex issues. Rima Alameddine, President of BD Interventional – Peripheral Intervention, emphasized this achievement, remarking that the Revello stent aims to elevate industry standards in iliac artery revascularization, enhancing patient outcomes through clinical innovation.

Technical Features of the Revello Stent

The Revello stent is unique due to its combination of flexibility and strength. Made of nitinol, the stent features a robust, ultra-thin polytetrafluoroethylene cover designed to keep the iliac arteries open. At the same time, the stent's flexible ends aim to minimize any trauma to healthy vascular segments during the procedure. Furthermore, tantalum markers provide excellent visibility under fluoroscopy, enabling physicians to navigate complex vascular anatomy effectively.

Precise Deployment System

For optimal placement, the Revello stent employs a tri-axial delivery system. This system is tailored for controlled deployment, integrating an atraumatic tip to facilitate smooth insertion, a stable sheath for easy release, and an intuitive adjustment wheel that allows for precise modifications during deployment. The Revello stent also comes in a variety of sizes, offering more diameter options than other auto-expandable stents currently available in the European market. This adaptability may significantly reduce access site complications, which is a concern with vascular procedures.

Clinical Evidence and Next Steps

The Revello stent was showcased at the prestigious LINC 2026 congress in Germany, where insights on its potential impacts on iliac interventions were shared. Dr. Michael Lichtenberg, a prominent physician and angiologist, noted the ongoing AGILITY clinical trial aimed at evaluating the stent's performance in patients battling PAD. This multicenter, prospective study is led by Dr. Sean Lyden from Cleveland Clinic, in collaboration with Dr. Lichtenberg in Europe.

According to Dr. Lichtenberg, "With the Revello stent, we have a remarkable option for treating iliac arteries. It stands out due to its high radial strength and low profile, and the tri-axial delivery system offers simple yet precise placement capabilities.”

Availability in the EU and Future Outlook

Following its CE marking, the Revello stent will be available in countries throughout Europe. However, it is crucial to note that in the United States, it remains an investigational device, restricted solely for research purposes under U.S. legislation. This delineation underscores BD's commitment to preparing for a future where innovative technologies can be fully implemented in addressing complex medical challenges.

In conclusion, BD's Revello vascular covered stent is more than just a product; it embodies a significant step forward in treating atherosclerotic conditions within the iliac arteries. As we anticipate its broader rollout in the EU, the potential for improved patient outcomes renders this development a remarkable advancement in vascular intervention.

For more about BD and its pioneering products, visit bd.com or follow them on social media platforms for regular updates.